Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2B Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study Publisher Pubmed



Zanjani H¹ ; Aminifard MN¹ ; Ghafourian A² ; Pourazizi M^{3, 4} ; Maleki A¹ ; Arish M¹ ; Shahrakipoor M⁵ ; Rohani MR¹ ; Abrishami M² ; Zare EK¹ ; Jalali FB¹
Source: Cornea Published:2017

Abstract

Purpose: Vernal keratoconjunctivitis (VKC) is a bilateral, chronic, external ocular inflammatory disorder that mainly affects patients in their first or second decade. This study was designed to compare tacrolimus and interferon alpha-2b (IFN alpha-2b) eye drops in the treatment of VKC. Methods: In this randomized, double-masked clinical trial, 40 consecutive patients with VKC were sent to a referral eye hospital in a tropical region southeast of Iran. Patients were randomly assigned to receive either 0.005% tacrolimus or IFN alpha-2b (1,000,000 units/cc). Chi-square and t tests were used for comparison of outcomes between both groups. Results: Mean 6 SD age was 11.1 6 5.2 years. Thirty-one patients (77.5%) were male. The mean duration of disease was 3.4 6 2.9 years. In this study, the signs and symptoms were significantly reduced in patients after treatment in both groups (P = 0.0001). In the tacrolimus group, all patients responded to treatment whereas only one subject in the IFN group failed to respond (P = 0.99). Side effects in both groups were mild and tolerable. Conclusions: This study indicated that both 0.005% tacrolimus and IFN alpha-2b are effective and appear to be safe in treatment of recalcitrant VKC. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved..